Iovance Biotherapeutics (NASDAQ:IOVA) Earns “Buy” Rating from HC Wainwright

Iovance Biotherapeutics (NASDAQ:IOVA)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $32.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q1 2025 earnings at ($0.23) EPS and Q4 2025 earnings at ($0.13) EPS.

Separately, Piper Sandler lowered their target price on Iovance Biotherapeutics from $10.00 to $7.50 and set a “neutral” rating on the stock in a research note on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Iovance Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $19.60.

Iovance Biotherapeutics Trading Down 19.4 %

Shares of IOVA stock opened at $4.24 on Friday. Iovance Biotherapeutics has a 1-year low of $3.62 and a 1-year high of $18.24. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -2.85 and a beta of 0.53. The stock’s fifty day simple moving average is $6.21 and its 200-day simple moving average is $8.56.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) EPS for the quarter, meeting analysts’ consensus estimates of ($0.26). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The firm had revenue of $73.69 million for the quarter, compared to the consensus estimate of $72.17 million. On average, sell-side analysts predict that Iovance Biotherapeutics will post -1.24 EPS for the current year.

Institutional Trading of Iovance Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. XML Financial LLC lifted its position in shares of Iovance Biotherapeutics by 7.4% in the third quarter. XML Financial LLC now owns 14,500 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,000 shares during the last quarter. Saturna Capital Corp lifted its position in shares of Iovance Biotherapeutics by 7.0% in the third quarter. Saturna Capital Corp now owns 20,553 shares of the biotechnology company’s stock worth $193,000 after buying an additional 1,353 shares during the last quarter. AlphaQuest LLC lifted its position in shares of Iovance Biotherapeutics by 63.6% in the fourth quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company’s stock worth $34,000 after buying an additional 1,794 shares during the last quarter. Creative Planning lifted its position in shares of Iovance Biotherapeutics by 2.6% in the third quarter. Creative Planning now owns 73,489 shares of the biotechnology company’s stock worth $690,000 after buying an additional 1,896 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG lifted its position in shares of Iovance Biotherapeutics by 10.1% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 21,318 shares of the biotechnology company’s stock worth $158,000 after buying an additional 1,950 shares during the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.